Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose vs Standard-dose Argatroban and Enoxaparin during ECMO
NCT07499037Phase 2Not yet recruiting
- Sponsor
- University Hospital Ostrava
- Start
- Jan 2027
- Primary completion
- Sep 2029
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of argatroban, enoxaparin in thrombosis, sponsored by University Hospital Ostrava. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
argatrobanenoxaparin
03
Conditions
thrombosis
Beyond the preview
Go deeper on NCT07499037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07499037.